f4cfbfdb-3861-4731-92d8-74e66a7ae5a7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 46
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.260
- WNT_BETA_CATENIN_SIGNALING+0.220
- MYOGENESIS+0.200
- APICAL_JUNCTION+0.160
- KRAS_SIGNALING_DN+0.100
- ANDROGEN_RESPONSE+0.080
- PANCREAS_BETA_CELLS+0.080
- UNFOLDED_PROTEIN_RESPONSE+0.080
- BILE_ACID_METABOLISM+0.060
- TGF_BETA_SIGNALING+0.060
Top 10 suppressed
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.460
- ALLOGRAFT_REJECTION-0.450
- MYC_TARGETS_V2-0.440
- INTERFERON_GAMMA_RESPONSE-0.410
- NOTCH_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
- GLYCOLYSIS-0.330
- INTERFERON_ALPHA_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d69e622a-6dee-48f3-bf06-7f6148d7472a | — | — | 0.852 |
| 2 | ca7ac1e1-4c44-40a5-8094-eeebc0c2c5a2 | — | — | 0.846 |
| 3 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.828 |
| 4 | TCGA-78-7161-01A-11R-2039-07 | — | cohortA3 | 0.827 |
| 5 | C3L-02165 | — | cohortA2 | 0.820 |
| 6 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.809 |
| 7 | 3ca8899d-3ed3-478b-a70c-919f68969d81 | — | — | 0.806 |
| 8 | e1d0ac40-05b3-4ab8-b64b-f42613e97cc7 | — | — | 0.804 |
| 9 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.800 |
| 10 | TCGA-A8-A0A4-01A-11R-A00Z-07 | — | A | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |